浏览全部资源
扫码关注微信
1.浙江药科职业大学药商学院,浙江 宁波;315500
2.浙江大学医学院附属杭州市第一人民医院药学部,杭州 310006
3.杭州市药品检查中心,杭州 310004
4.上药控股宁波医药股份有限公司,浙江 宁波 315000
5.华东医药供应链管理(杭州)有限公司,杭州 310018
Published:15 May 2023,
Received:23 January 2023,
Revised:05 April 2023,
扫 描 看 全 文
施能进,丁静,王刚等.药品零售企业网售处方药风险及对策研究 Δ[J].中国药房,2023,34(09):1031-1037.
SHI Nengjin,DING Jing,WANG Gang,et al.Study on the risk and countermeasure of prescription drugs sold online by drug retail enterprises[J].ZHONGGUO YAOFANG,2023,34(09):1031-1037.
施能进,丁静,王刚等.药品零售企业网售处方药风险及对策研究 Δ[J].中国药房,2023,34(09):1031-1037. DOI: 10.6039/j.issn.1001-0408.2023.09.02.
SHI Nengjin,DING Jing,WANG Gang,et al.Study on the risk and countermeasure of prescription drugs sold online by drug retail enterprises[J].ZHONGGUO YAOFANG,2023,34(09):1031-1037. DOI: 10.6039/j.issn.1001-0408.2023.09.02.
目的
2
分析药品零售企业网售处方药风险,为网售处方药的风险防控提供对策建议。
方法
2
采用层次分析法构建药品零售企业网售处方药风险层次结构模型,再进行风险判断矩阵的归一化权重计算和一致性检验;采用德尔菲专家调查法对123对评价指标进行多轮风险研判,开展模糊定量研究。
结果
2
药品零售企业网售处方药风险中的处方调剂及审核风险(6.48%)、先药后方风险(5.48%)、合理用药指导风险(4.99%)、非正常用途购买药品风险(4.97%)、“首诊、非慢性病、非常见病”风险(4.43%)、退货药品质量安全风险(4.34%)、监管技术应用风险(4.06%)为高风险点;药品零售企业(连锁)网售处方药的总体风险为38.67%,药品零售企业(单体)网售处方药的总体风险为61.33%,两者之间相差22.66%。
结论
2
药品零售企业网售处方药高风险指标有7个,其中处方调剂及审核风险、先药后方风险、合理用药指导风险为排名前3位的高风险点;药品零售企业(单体)网售处方药的风险要高于药品零售企业(连锁)。建议监管部门重点关注并规范药品零售企业(单体)的网售处方药行为,鼓励药品零售企业(连锁)建立系统的处方药网售流程;对于网售处方药的高风险点,建议监管部门和药品零售企业重点关注并采取有效风险防控措施,以保障老百姓网购处方药的安全用药权益。
OBJECTIVE
2
To analyze the risks of prescription drugs sold online by drug retail enterprises, and to provide countermeasures and suggestions for risk prevention and control of prescription drugs sold online.
METHODS
2
The risk hierarchy structure model of prescription drugs sold online by drug retail enterprises was constructed by using analytic hierarchy process. Multiple rounds of risk research and judgment were carried out on 123 pairs of evaluation indicators by using Delphi expert survey method. The normalized weight calculation and consistency test of risk judgment matrix were carried out to perform fuzzy quantitative research.
RESULTS
2
The risk of prescription dispensing and review (6.48%), the risk of drug first and prescription later (5.48%), the risk of rational drug use guidance (4.99%), the risk of buying drugs by abnormal channel (4.97%), the risk of “first diagnosis, non-chronic disease and non-common disease” (4.43%), and the quality and safety risk of returned drugs (4.34%) and the application risk of regulatory technology (4.06%) were high risks; the overall risk of drug retail enterprises (chain) selling prescription drugs online was 38.67%, and the overall risk of drug retail enterprises (individual) selling prescription drugs online was 61.33%, with a difference of 22.66% between them.
CONCLUSIONS
2
There were 7 high-risk indicators for prescription drugs sold online by drug retail enterprises. Among them, the risk of prescription dispensing and review, the risk of drug first and prescription later, and the risk of rational drug use guidance are the top three high-risk points. The risk of prescription drugs sold online by drug retail enterprises (individual) is higher than that of drug retail enterprises (chain). It is recommended that regulatory authorities focus on and regulate the prescription drugs sold online by drug retail enterprises (individual), and encourage drug retail enterprises (chain) to establish a systematic online sales process for prescription drugs; for high-risk points of prescription drugs sold online, it is recommended that regulatory authorities and drug retail enterprises focus on it and take effective risk prevention and control measures to ensure the safe use of prescription drugs by the general public.
药品零售企业网售处方药风险监管单体连锁
prescription drugs sold onlineriskregulationmonomerschain
张玉青,张然,侯志翠. 药品互联网经营的风险与对策[J]. 中国质量监管,2022(2):80-83.
刘琳. 网售处方药的风险识别、研判及应对[J]. 卫生经济研究,2022(4):19-23.
王丽丽. 浅析药品网络销售发展中的问题及法律对策[J]. 中国卫生法制,2022,30(6):34-36,43.
GONG Y H,JIANG N,CHEN Z Y,et al. Over-the-counter antibiotic sales in community and online pharmacies,China[J]. Bull World Health Organ,2020,98(7):449-457.
全国人民代表大会常务委员会.中华人民共和国药品管理法[J]. 中华人民共和国全国人民代表大会常务委员会公报,2019(5):771-788.
万静. 药品网络销售进入规范化严监管时期[N]. 法治日报,2022-12-09(6).
张敏. 网售药品首批禁止清单出炉 行业进入规范化严监管时期[N]. 证券日报,2022-12-02(A03).
FINCHAM J E. Negative consequences of the widespread and inappropriate easy access to purchasing prescription medications on the internet[J]. Am Health Drug Benefits,2021,14(1):22-28.
邵蓉,王梦媛,颜建周,等. 我国网售处方药报销面临的问题及对策分析:基于美国药品福利管理模式[J]. 中国卫生政策研究,2016,9(4):31-36.
国家食品药品监督管理总局.国家食品药品监督管理总局关于修改《药品经营质量管理规范》的决定[J]. 中华人民共和国国务院公报,2017(7):75-92.
韩利,梅强,陆玉梅,等. AHP-模糊综合评价方法的分析与研究[J]. 中国安全科学学报,2004,14(7):86-89.
LIU Q Z. Identifying and correcting the defects of the Saaty analytic hierarchy/network process:a comparative study of the Saaty analytic hierarchy/network process and the Markov chain-based analytic network process[J]. Oper Res Perspect,2022,9:100244.
谭跃进. 定量分析方法[M]. 3版. 北京:中国人民大学出版社,2012:1-156.
刘丽华. 药品网络销售监管问题研究[D]. 海口:海南大学,2020.
吴永新,朱自来,刘万里,等. 层次分析法分析医院门诊药房退药原因及改进措施[J]. 中国处方药,2020,18(9):7-9.
国家卫生健康委,国家中医药局. 卫生健康委 中医药局关于印发互联网诊疗管理办法(试行)等3个文件的通知[J]. 中华人民共和国国务院公报,2019(2):49-58.
0
Views
4
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution